Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

HER2HEART-US: Primary Prevention of Cardiotoxicity in Breast Cancer Patients Receiving HER2-directed Therapy: a Pilot 2x2 Factorial Randomized Controlled Trial

NCT06844669 is registered in ClinicalTrials.gov with Washington University School of Medicine as lead sponsor.

NCT NCT06844669
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06844669 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
HER2HEART-US: Primary Prevention of Cardiotoxicity in Breast Cancer Patients Receiving HER2-directed Therapy: a Pilot 2x2 Factorial Randomized Controlled Trial
Lead sponsor
Washington University School of Medicine
Phase
Phase 2
Overall status
Terminated
Start date
April 16, 2025
Completion date
May 7, 2026
Enrollment
7 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

her2+ breast cancer, her2-positive breast cancer